What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?  

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you consolidate first remission with autologous or allogeneic hematopoietic cell transplant? 

Answer from: Medical Oncologist at Academic Institution